TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years

Accessibility StatementSkip Navigation Clinical remission rates were over 85% for both TREMFYA maintenance doses at 96 weeks in both the Phase 3 GRAVITI and GALAXI studies At Week 96 (as observed)*:    TREMFYA 100 mg q8w TREMFYA 200 mg q4w | Clinical remission | | | | --- | --- | --- | | | 92.0% | 93.4% | | GRAVITI | 86.7% | 87.1% | | GALAXI 2, 3 (pooled) | | | | Endoscopic response | 65.0% | 65.1% | | GRAVITI | 73.6% | 70.7% | | GALAXI 2, 3 (pooled) | | | | Endoscopic remission | 41.5% | 46.0% | | GR ...